for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC); or as a single agent, for the treatment of adults with metastatic ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced nasopharyngeal carcinoma. The FDA has approved Akeso’s penpulimab-kcqx, a ...

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. The United States Food and Drug Administration (FDA) has approved ...

The FDA has approved penpulimab with chemotherapy for first-line recurrent/metastatic non-keratinizing nasopharyngeal carcinoma and alone after prior treatment. The FDA approved penpulimab-kcqx in ...

Review of "Components of Hospital Perioperative Infrastructure Can Overcome the Weekend Effect in Urgent General Surgery Procedures" by Kothari AN, Zapf MA, Blackwell RH, Markossian T, Chang V, Mi ...

The trial compared the combo against the investigator’s choice of tyrosine kinase inhibitor monotherapy in the unresectable or advanced hepatocellular carcinoma patient group. Credit: ...

1State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of ...